Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%?

Roche’s Glofitamab: ASCO 2022Roche revealed the impressive findings from the Phase II expansion study of Glofitamab in the patients with ...